Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.

Trial Details

NCT ID
NCT07078929
Phase
PHASE1
Sponsor
Chulalongkorn University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CD19-IL7Ra CAR-T cells
Locations (sample)
  • Bangkok, Bangkoknoi, Thailand|13.75398,100.50144
  • Chiang Mai, Mueang Chiang Mai District, Thailand|18.79038,98.98468
  • Bangkok, Pathumwan, Thailand|13.75398,100.50144

Key Eligibility Criteria

  • Participants must have relapsed, or refractory ALL treated with at least one lines of therapy. Disease must have either progressed after the last r…
  • \- Participant with Philadelphia Chromosome positive ALL are eligible if the progressed, had stable disease or relapsed after one line of therapy i…
  • The participant's disease must be CD19 positive either by immunohistochemistry or flow cytometry analysis
  • Age 1 - 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →